Last reviewed · How we verify
Antioxidant therapies
Antioxidant therapies work by neutralizing reactive oxygen species and free radicals to reduce oxidative stress and cellular damage.
Antioxidant therapies work by neutralizing reactive oxygen species and free radicals to reduce oxidative stress and cellular damage. Used for Oxidative stress-related conditions (non-specific; exact indications vary by formulation and clinical context).
At a glance
| Generic name | Antioxidant therapies |
|---|---|
| Sponsor | Mansoura University Hospital |
| Drug class | Antioxidant agent |
| Modality | Small molecule |
| Therapeutic area | Multiple (Cardiovascular, Neurology, Oncology supportive care, General) |
| Phase | FDA-approved |
Mechanism of action
These therapies employ various compounds (such as vitamins E and C, selenium, or other antioxidant agents) that donate electrons to unstable free radicals, preventing them from damaging cellular components like lipids, proteins, and DNA. By reducing oxidative stress, antioxidant therapies aim to mitigate inflammation, slow disease progression, and protect tissues from degenerative processes associated with various chronic conditions.
Approved indications
- Oxidative stress-related conditions (non-specific; exact indications vary by formulation and clinical context)
Common side effects
- Gastrointestinal upset
- Headache
- Fatigue
Key clinical trials
- Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity (PHASE2)
- Epigallocatechin Gallate (EGCG) as a Flushing Agent During Full Pulpotomy in Mature Permanent Molars With Irreversible Pulpitis (NA)
- Ascorbate in Myelodysplastic Syndrome (PHASE2)
- The Efficacy of Tocotrienol Rich Fraction for Liver Protection in Adult Patients With Alcoholic Fatty Liver Disease (AFLD) (PHASE2)
- Impact of Date Consumption on Metabolic Control and Oxidative Stress in Patients With Type 2 Diabetes (NA)
- A 16-week Clinical Study Investigating a Dark Spot Corrector Serum in Women With Moderate Discrete Hyperpigmentation (NA)
- Impact of Prehabilitation and Comprehensive Follow-up in Women With Breast Cancer (NA)
- Non-Pharmacological Interventions for Neurotoxicity in Hematologic Patients Receiving CAR-T Therapy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Antioxidant therapies CI brief — competitive landscape report
- Antioxidant therapies updates RSS · CI watch RSS
- Mansoura University Hospital portfolio CI